Ellen Seely, MD

Ellen Seely, MD


Vice Chair, Faculty Development
Department of Medicine
Director of Clinical Research, Endocrinology, Diabetes and Hypertension Division
Brigham & Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, MA

Related Videos

Although it’s understood that there are a panoply of glucocorticoid-related side effects in adults with CAH, what are the most serious and prevalent morbidities that you’ve had to manage in your practice? Video

Although it’s understood that there are a panoply of glucocorticoid-related side effects in adults with CAH, what are the most serious and prevalent morbidities that you’ve had to manage in your practice?

Can you be kind enough to give us some background regarding your research and clinical experience identifying and managing pediatric and adult patients with CAH? Video

Can you be kind enough to give us some background regarding your research and clinical experience identifying and managing pediatric and adult patients with CAH?

Based on your experience following persons with CAH, from their pediatric years into adulthood, can you characterize the disease burden of CAH? Video

Based on your experience following persons with CAH, from their pediatric years into adulthood, can you characterize the disease burden of CAH?

Given the long-term sequelae of supra-physiologic dosing of glucocorticoids for CAH, what therapeutic strategies are being considered to uncouple the cortisol and androgen pathways? Video

Given the long-term sequelae of supra-physiologic dosing of glucocorticoids for CAH, what therapeutic strategies are being considered to uncouple the cortisol and androgen pathways?

Can you explain the difference between CRH (corticotropin releasing hormone) and CRF (corticotropin releasing factor), or are you referring to the same hormonal factor? Video

Can you explain the difference between CRH (corticotropin releasing hormone) and CRF (corticotropin releasing factor), or are you referring to the same hormonal factor?

From a near future perspective, what do you believe are the most promising approaches to reducing metabolic, cardiometabolic, and related morbidities in adults with CAH? Video

From a near future perspective, what do you believe are the most promising approaches to reducing metabolic, cardiometabolic, and related morbidities in adults with CAH?

If the rationale for upstream decoupling of the androgen and cortisol pathways at the level of CRF inhibition is confirmed, what are the potential advantages in terms of reducing glucocorticoid dose? Video

If the rationale for upstream decoupling of the androgen and cortisol pathways at the level of CRF inhibition is confirmed, what are the potential advantages in terms of reducing glucocorticoid dose?

What are the typical glucocorticoid replacement doses used for person with CAH? Video

What are the typical glucocorticoid replacement doses used for person with CAH?

Since you’ve treated adults with CAH who have been on glucocorticoids for many years, what are the long-term side effects and complications that have required management? Video

Since you’ve treated adults with CAH who have been on glucocorticoids for many years, what are the long-term side effects and complications that have required management?